# Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

> **NCT00049842** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 540 (actual)

## Conditions studied

- Chronic Hepatitis C
- Liver Fibrosis

## Interventions

- **BIOLOGICAL:** peginterferon alfa-2b (SCH 54031)

## Key facts

- **NCT ID:** NCT00049842
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049842, "Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00049842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*